June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells
Author Affiliations & Notes
  • Ping Yang
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Nicholas Anthony Besley
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Scott W Lallier
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Zixuan Shao
    Allegro Ophthalmics, California, United States
  • John Y Park
    Allegro Ophthalmics, California, United States
  • Hampar Karageozian
    Allegro Ophthalmics, California, United States
  • Vicken Karageozian
    Allegro Ophthalmics, California, United States
  • Glenn J Jaffe
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Ping Yang, None; Nicholas Besley, None; Scott Lallier, None; Zixuan Shao, Allegro Ophthalmics (E); John Park, Allegro Ophthalmics (E); Hampar Karageozian, Allegro Ophthalmics (E); Vicken Karageozian, Allegro Ophthalmics (E); Glenn Jaffe, None
  • Footnotes
    Support  This work was supported, in part, by Unrestricted Research to Prevent Blindness Grant and the NIH Core Grant [P30EY005722].
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2697. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ping Yang, Nicholas Anthony Besley, Scott W Lallier, Zixuan Shao, John Y Park, Hampar Karageozian, Vicken Karageozian, Glenn J Jaffe; Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2697.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Risuteganib (RSG) is a novel synthetic peptide that regulates integrin functions and has shown promising efficacy in an intermediate dry AMD phase 2 clinical study. We previously reported that RSG protected against retinal pigment epithelial (RPE) cell injury induced by hydroquinone (HQ), a major oxidant in cigarette smoke and atmospheric pollutants, agents implicated in age-related macular degeneration (AMD) pathogenesis. Many transcription factors (TFs) are important regulators of genes that control cellular response to oxidative stress. Herein, we investigate the effect of RSG on expression of several TFs regulated by HQ in human RPE cells.

Methods : Cultured human RPE cells in triplicate wells were treated with HQ at different concentrations in the presence or absence of RSG (400 µM, Allegro Ophthalmics, LLC) for various treatment times. Expression of TF genes associated with cellular stress response, including activating transcription factor 3 (ATF3), DNA damage-inducible transcript 3 (DDIT3; encodes the multifunctional TF, CHOP), and DNA-binding protein inhibitors (ID-2 and ID-3), were analyzed by qPCR. Expression of ATF3, CHOP, nuclear factor erythroid 2-related factor 2 (NRF2), and X-box binding protein 1s (XBP1) were evaluated by Western blot.

Results : Compared to untreated cells, HQ significantly increased mRNA expression of ATF3, DDIT3, ID2 and ID3 (P<0.05). RSG+HQ cotreatment significantly further upregulated HQ-induced ATF3 and DDIT3 (P<0.05) and decreased HQ-induced ID2 and ID3 mRNA levels (P<0.05). Levels of ATF3, Nrf2, CHOP, XBP1 proteins were significantly upregulated by HQ and further upregulated by RSG+HQ cotreatment (P<0.05).

Conclusions : RSG modulated multiple transcription factors involved in oxidant injury pathways, supporting a multifunctional role of RSG on RPE cells against oxidative stress.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×